Gaucher disease

Gaucher disease
Name	Gaucher disease
Caption	Bone marrow aspirate showing Gaucher cells
Synonyms	Glucocerebrosidase deficiency
Field	Hematology, Genetics, Pediatrics
Symptoms	Hepatosplenomegaly, anemia, thrombocytopenia, bone pain
Complications	Bone crises, pulmonary hypertension, malignancy
Onset	Variable; childhood or adulthood
Duration	Chronic
Causes	Mutations in GBA gene
Diagnosis	Enzyme assay, genetic testing, imaging
Treatment	Enzyme replacement therapy, substrate reduction therapy
Frequency	1 in 40,000–60,000; higher in certain populations

Gaucher disease is an inherited lysosomal storage disorder caused by deficient activity of the enzyme glucocerebrosidase due to variants in the GBA gene. The condition produces multisystem manifestations including visceral enlargement, hematologic abnormalities, and skeletal disease, with clinical variability ranging from asymptomatic adults to severe infantile forms. Diagnosis relies on biochemical and genetic testing, and treatment options now include enzyme replacement and substrate reduction therapies that have transformed outcomes.

Signs and symptoms

Clinical features often include progressive splenomegaly and hepatomegaly presenting as abdominal distension, pancytopenia manifesting as anemia and thrombocytopenia with bleeding tendency, and bone involvement with crises and avascular necrosis. Neurological manifestations appear in neuronopathic variants, with oculomotor abnormalities, seizures, and developmental delay leading to presentations in pediatric settings such as St. Jude Children's Research Hospital or referrals to tertiary centers like Mayo Clinic. Patients may develop pulmonary symptoms including dyspnea and pulmonary hypertension seen in cardiopulmonary clinics such as Cleveland Clinic; growth failure and endocrine disturbances prompt evaluation at centers like Johns Hopkins Hospital. Other complications include splenic infarction, portal hypertension requiring attention in hepatology units such as Mount Sinai Hospital, and an elevated risk of hematologic malignancies managed in collaboration with institutions such as Dana–Farber Cancer Institute.

Genetics and pathophysiology

The disorder is caused by biallelic pathogenic variants in the GBA gene on chromosome 1, first characterized through molecular studies involving researchers at University of California, San Francisco and Massachusetts General Hospital. Deficiency of glucocerebrosidase leads to accumulation of glucosylceramide within macrophage-lineage cells, creating characteristic Gaucher cells that infiltrate organs. Genotype–phenotype correlations were explored in cohorts from Mount Sinai School of Medicine and University College London, revealing common variants such as N370S and L444P with differing clinical courses; heterozygous GBA variants are also associated with increased risk for neurodegenerative disorders observed in studies at Albert Einstein College of Medicine and University of Toronto. Cellular mechanisms involve disrupted lysosomal function and secondary inflammatory cascades elucidated in work from National Institutes of Health and Scripps Research.

Diagnosis

Diagnosis is established by low leukocyte glucocerebrosidase activity measured in specialized laboratories affiliated with institutions such as Mayo Clinic Laboratories or ARUP Laboratories and confirmed by sequencing of GBA through genetic services at centers like GeneDx and Invitae. Imaging modalities including MRI and plain radiography performed at facilities like Hospital for Special Surgery identify bone marrow infiltration, Erlenmeyer flask deformity, and avascular necrosis. Organomegaly is documented with ultrasound or CT at radiology departments such as Massachusetts General Hospital Radiology. Biomarkers including chitotriosidase and CCL18 are used in monitoring with assays developed at research sites including Karolinska Institute and University of Barcelona. Prenatal diagnosis and carrier screening are offered via programs at Johns Hopkins University and commercial laboratories.

Classification and types

Clinical classification separates non-neuronopathic and neuronopathic phenotypes originally delineated in seminal descriptions from institutions like Harvard Medical School and University of Pennsylvania. Type distinctions include perinatal lethal, acute neuronopathic (infantile), subacute neuronopathic (juvenile), and chronic non-neuronopathic forms recognized in registries maintained by organizations such as the International Gaucher Alliance and studies from Oxford University. Classification schemes incorporate age of onset, neurological involvement, and genotype, influenced by population studies in Ashkenazi Jewish cohorts documented at Sheba Medical Center and community screening programs at Tel Aviv University.

Treatment and management

Enzyme replacement therapy (ERT) with recombinant glucocerebrosidase agents developed by companies collaborating with research centers like Genzyme and Shire is standard for visceral and hematologic disease, with infusions administered at infusion centers affiliated with hospitals such as Cleveland Clinic and UCSF Medical Center. Substrate reduction therapy (SRT) using oral agents emerged from trials conducted at National Institutes of Health and pharmaceutical collaborations for patients intolerant of ERT. Supportive management includes splenectomy historically performed in surgical units at Mayo Clinic but now reserved for refractory cases, orthopedic interventions managed by surgeons at Hospital for Special Surgery, and multidisciplinary care involving pain specialists at institutions like Johns Hopkins Hospital. Emerging approaches including pharmacological chaperones and gene therapy are under investigation in trials run by academic centers including Stanford University and University of Pennsylvania.

Prognosis and complications

Prognosis varies by type, with non-neuronopathic patients achieving near-normal life expectancy with modern therapy as shown in longitudinal studies at Mount Sinai Hospital and Royal Free Hospital. Neuropathic forms carry significant morbidity and early mortality despite interventions reported in pediatric series at Great Ormond Street Hospital. Long-term complications include osteonecrosis, fractures, pulmonary hypertension, and increased incidence of multiple myeloma and other hematologic malignancies described in cohorts from Brigham and Women's Hospital and Memorial Sloan Kettering Cancer Center. Lifelong surveillance is coordinated through centers of excellence such as European Gaucher Alliance-affiliated clinics and national registries maintained by entities like Genetic Alliance.

Category:Lysosomal storage diseases